Skip to content

Avanos Medical AVNS Options canceled (in dollars per share)

Options canceled (in dollars per share) at other companies

Baxter International logo
Baxter InternationalBAX
$41.84-12.8%
Henry Schein logo
Henry ScheinHSIC
$85.51
Corvel logo
CorvelCRVL

Other financials

Income statement

See full
Revenue$182.2M+8.8%
Gross profit$94.2M+4.9%
Operating income$8.9M-13.6%
Net income$5.1M-22.7%
EPS (diluted)$0.11-21.4%

Balance sheet

See full
Cash & equivalents$65.6M-32.4%
Total debt$138.4M-1.8%
Total equity$782.1M-6.8%
Total assets$1.1B-5.2%

Cash flow

See full
Operating cash flow-$12.3M-148%
CapEx$4.3M-35.8%
Free cash flow-$16.6M-187%

Valuation

See full
Market cap$1.17B-1.2%
Enterprise value$1.24B+3.0%
P/S1.6×-0.1×

Profitability

See full
Gross margin50%-4.6pp
Operating margin-9.1%-4.2pp
Net margin-10.4%-4.7pp
FCF margin1.6%-14.9pp

Returns & leverage

See full
Return on equity-9.2%-3.9pp
Debt / equity0.2×0.0×
Current ratio2.5×-0.1×

Where this comes from

Reported directly by Avanos Medical in its filing.

Tagged under the XBRL concept us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice.

The official record: Avanos Medical’s 10-K, filed February 24, 2026, on SEC EDGAR. View the filing →

Ask your AI about Avanos Medical's options canceled (in dollars per share).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Avanos Medical's options canceled (in dollars per share)?
Avanos Medical (AVNS) reported options canceled (in dollars per share) of $31.83 in Q4 2025.
How has Avanos Medical's options canceled (in dollars per share) changed year-over-year?
Avanos Medical's options canceled (in dollars per share) decreased by 14.8% year-over-year, from $37.36 to $31.83.
What does options canceled (in dollars per share) mean?
The weighted average price per share associated with forfeited stock options during the period. This provides context on the potential value of equity incentives that did not vest, helping investors understand the impact of employee retention on compensation expense.